CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences:
UBS Global Healthcare Conference 2024
Wednesday, November 13, 2024 at 2:00 P.M. EST
The presentation will be webcast live and may be accessed here.
7th Annual Evercore HealthCONx Conference
Wednesday, December 4, 2024 at 9:35 A.M. EST
Piper Sandler 36th Annual Healthcare Conference
Thursday, December 5, 2024 at 8:30 A.M. EST
The fireside chats will be webcast live and can be accessed by visiting Madrigal’s Investor Relations Events page.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH. For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Christopher Frates, This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$301.76 |
| Daily Change: | -6.02 -1.96 |
| Daily Volume: | 117,573 |
| Market Cap: | US$6.580B |
March 11, 2025 January 13, 2025 January 03, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
